Global COVID Testing Kit Research Report—Forecast till 2027

Global COVID Testing Kit Research Report—Forecast till 2027

Market Dynamics

Global COVID-19 Diagnostics Market is estimated to exhibit a CAGR of 6.28% to surpass USD 96,293.9 Million during the review period. COVID-19 is a contagious infection caused due to the coronavirus and attacks on respiratory systems. This virus is spreading rapidly hence the whole world is facing a COVID-19 pandemic. As per the research of Worldometer, there have been 4.71 million COVID-19 cases worldwide till 18 May 2020. The global market growth is propelled by the increasing number of emergency use authorizations (EUAs) for diagnostic kits & devices and developments & support by non-medical device/diagnostic companies.

Market Segmentation
Global COVID-19 Diagnostics Market has been categorized based on Type, Technology, and End Users. In terms of type segment, the global market has been divided into molecular tests and serology tests.
Based on technology type, the market has been segmented into RT-PCR, isothermal amplification, CRISPR, ELISA, hybridization, and others.
By End User segment, the COVID-19 diagnostics market has been classified into hospitals, public health labs, private or commercial labs, and others.

Regional Analysis
Geographically, the Global COVID-19 Diagnostics Market has been segmented into Europe, the Americas, Asia-Pacific, and the Middle East & Africa.
Europe contributes the largest market share of the COVID-19 diagnostics owing to the high number of infected patients in the region.
According to European Centre for Disease Control and Prevention, as of 19 May 2020, 1 317 267 cases have been reported in the European Union (EU) and European Economic Area (EEA) and the UK. Moreover, the increased COVID-19 morbidity and mortality observed among residents in long-term care facilities (LTCF) in EU/EEA countries acts as a major hurdle for disease prevention and control in such settings.
The second-largest market for COVID-19 diagnostics is estimated to be the Americas during the review period. The regional market growth is driven by the fastest outbreak of highly infectious acute respiratory disease COVID-19 and the presence of major manufacturers. Moreover, the increasing product launches by major players are also propelling the market rise during the assessment period.
Asia-Pacific is estimated to be the rapid-growing market due to the increasing number of COVID-19 cases, government & private funding for research & development for effective diagnosis during the forecast period.
The market in the Middle East & Africa is estimated to register steady growth owing to increasing COVID-19 cases and government regulations to improve patient care.

Major Players
The Prominent Players in the Global COVID-19 Diagnostics Market are Becton, Dickinson & Company (US), Bio-Rad Laboratories (US), Danaher Corporation (US), Abbott (US), F. Hoffmann-La Roche Ltd (Switzerland), Biomerieux SA (France), Genmark Diagnostics (US), Thermo Fisher Scientific (US), Qiagen (Germany), and Siemens AG (Germany).

COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

TABLE OF CONTENT
1 EXECUTIVE SUMMARY
1.1 OVERVIEW 14

1.2 MARKET SYNOPSIS 14

2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY 15

2.2 RESEARCH OBJECTIVE 15

3 RESEARCH METHODOLOGY
3.1 OVERVIEW 16

3.2 DATA MINING 16

3.3 SECONDARY RESEARCH 16

3.4 PRIMARY RESEARCH 18

3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 18

3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 19

3.5 FORECASTING METHODS 20

3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21

3.6.1 BOTTOM-UP APPROACH 21

3.6.2 TOP-DOWN APPROACH 22

3.7 DATA TRIANGULATION 22

3.8 VALIDATION 22

3.9 ASSUMPTIONS AND LIMITATIONS 23

3.9.1 ASSUMPTIONS AND LIMITATIONS 23

3.9.2 MARKET FACTORS 23

4 MARKET DYNAMICS
4.1 OVERVIEW 25

4.2 DRIVERS 26

4.2.1 INCREASING NUMBER OF COVID-19 CASES 26

4.2.2 GOVERNMENT AND PRIVATE FUNDS AS WELL AS SUPPORT FOR RESEARCH & DEVELOPMENT 26

4.2.3 RISING NUMBER OF EMERGENCY USE AUTHORIZATIONS (EUA) FOR DIAGNOSTIC KITS AND DEVICES 26

4.2.4 DEVELOPMENTS AND SUPPORT BY NON-MEDICAL DEVICE/DIAGNOSTIC COMPANIES 27

4.3 RESTRAINTS 28

4.3.1 RESTRICTIONS ON EXPORT OF DIAGNOSTIC KITS 28

4.3.2 ACCURACY OF TEST RESULTS 28

4.4 OPPORTUNITIES 28

4.4.1 DEVELOPMENT OF QUICK, ACCURATE, AND AFFORDABLE TESTS 28

4.4.2 COLLABORATION OF MAJOR PLAYERS WITH SMALL PLAYERS 28

5 MARKET FACTOR ANALYSIS
5.1 PORTER’S FIVE FORCES MODEL 29

5.1.1 THREAT OF NEW ENTRANTS 29

5.1.2 BARGAINING POWER OF SUPPLIERS 30

5.1.3 THREAT OF SUBSTITUTES 30

5.1.4 BARGAINING POWER OF BUYERS 30

5.1.5 INTENSITY OF RIVALRY 30

5.2 SUPPLY CHAIN ANALYSIS 31

5.2.1 R&D AND DESIGNING 32

5.2.2 MANUFACTURING 32

5.2.3 DISTRIBUTION 32

5.2.4 MARKETING & SALES 32

5.2.5 POST-SALES MONITORING 32

5.3 IMPACT OF COVID-19 ON SUPPLY OF DIAGNOSTIC DEVICES 32

6 COVID-19 DIAGNOSTICS MARKET, BY TYPE
6.1 OVERVIEW 33

6.2 MOLECULAR TESTS 34

6.3 SEROLOGY TESTS 36

7 COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 OVERVIEW 38

7.2 RT-PCR 40

7.3 ISOTHERMAL AMPLIFICATION 40

7.4 CRISPR 41

7.5 ELISA 42

7.6 HYBRIDIZATION 43

7.7 OTHERS 43

8 COVID-19 DIAGNOSTICS MARKET, BY END USER
8.1 OVERVIEW 44

8.2 HOSPITALS 45

8.3 PUBLIC HEALTH LABS 46

8.4 PRIVATE OR COMMERCIAL LABS 47

9 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY REGION
9.1 OVERVIEW 48

9.2 EUROPE 50

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.2.1 WESTERN EUROPE 52

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.2.1.1 GERMANY 53

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.2.1.2 SPAIN 54

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.2.1.3 ITALY 55

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.2.1.4 UK 56

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.2.1.5 FRANCE 57

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.2.1.6 REST OF WESTERN EUROPE 58

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.2.2 EASTERN EUROPE 59

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.3 AMERICAS 61

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.3.1 NORTH AMERICA 63

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.3.1.1 US 64

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.3.1.2 CANADA 65

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.3.2 LATIN AMERICA 66

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.4 ASIA-PACIFIC 68

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.4.1 INDIA 70

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.4.2 AUSTRALIA 71

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.4.3 SOUTH KOREA 72

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.4.4 JAPAN 73

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.4.5 CHINA 74

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.4.6 REST OF ASIA-PACIFIC 75

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.5 MIDDLE EAST & AFRICA 77

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.5.1 MIDDLE EAST 79

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

9.5.2 AFRICA 80

COVID-19 DIAGNOSTICS MARKET, BY TYPE

COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY

COVID-19 DIAGNOSTICS MARKET, BY END USER

10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW 81

10.2 MAJOR PLAYERS IN THE GLOBAL COVID-19 DIAGNOSTICS MARKET 81

10.3 GLOBAL COVID-19 DIAGNOSTICS MARKET INSIGHTS 82

10.4 COMPETITIVE BENCHMARKING 83

10.5 COMPETITOR DASHBOARD 84

10.6 MAJOR GROWTH STRATEGIES IN THE GLOBAL COVID-19 DIAGNOSTICS MARKET 85

10.7 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL COVID-19 DIAGNOSTICS MARKET 86

10.8 KEY DEVELOPMENTS & GROWTH STRATEGIES 86

10.8.1 PRODUCT LAUNCHES 87

10.8.2 ACQUISITIONS 88

10.8.3 CONTRACTS 88

11 COMPANY PROFILES
11.1 BECTON, DICKINSON AND COMPANY 89

11.1.1 COMPANY OVERVIEW 89

11.1.2 FINANCIAL OVERVIEW 90

11.1.3 PRODUCTS/SERVICES OFFERED 90

11.1.4 KEY DEVELOPMENTS 91

11.1.5 SWOT ANALYSIS 91

11.1.6 KEY STRATEGIES 91

11.2 BIO-RAD LABORATORIES, INC. 92

11.2.1 COMPANY OVERVIEW 92

11.2.2 FINANCIAL OVERVIEW 92

11.2.3 PRODUCTS/SERVICES OFFERED 93

11.2.4 KEY DEVELOPMENTS 93

11.2.5 SWOT ANALYSIS 94

11.2.6 KEY STRATEGIES 94

11.3 DANAHER CORPORATION 95

11.3.1 COMPANY OVERVIEW 95

11.3.2 FINANCIAL OVERVIEW 96

11.3.3 PRODUCTS/SERVICES OFFERED 96

11.3.4 KEY DEVELOPMENTS 97

11.3.5 SWOT ANALYSIS 97

11.3.6 KEY STRATEGIES 97

11.4 ABBOTT 98

11.4.1 COMPANY OVERVIEW 98

11.4.2 FINANCIAL OVERVIEW 99

11.4.3 PRODUCTS/SERVICES OFFERED 99

11.4.4 KEY DEVELOPMENTS 100

11.4.5 SWOT ANALYSIS 100

11.4.6 KEY STRATEGIES 100

11.5 F. HOFFMANN-LA ROCHE LTD 101

11.5.1 COMPANY OVERVIEW 101

11.5.2 FINANCIAL OVERVIEW 102

11.5.3 PRODUCTS/SERVICES OFFERED 102

11.5.4 KEY DEVELOPMENTS 103

11.5.5 SWOT ANALYSIS 103

11.5.6 KEY STRATEGIES 103

11.6 BIOMERIEUX SA 104

11.6.1 COMPANY OVERVIEW 104

11.6.2 FINANCIAL OVERVIEW 104

11.6.3 PRODUCTS/SERVICES OFFERED 105

11.6.4 PRODUCTS/SERVICES PIPELINE 105

11.6.5 KEY DEVELOPMENTS 105

11.6.6 SWOT ANALYSIS 106

11.6.7 KEY STRATEGIES 106

11.7 GENMARK DIAGNOSTICS, INC. 107

11.7.1 COMPANY OVERVIEW 107

11.7.2 FINANCIAL OVERVIEW 107

11.7.3 PRODUCTS/SERVICES OFFERED 108

11.7.4 KEY DEVELOPMENTS 108

11.7.5 SWOT ANALYSIS 108

11.7.6 KEY STRATEGIES 108

11.8 THERMO FISHER SCIENTIFIC INC. 109

11.8.1 COMPANY OVERVIEW 109

11.8.2 FINANCIAL OVERVIEW 109

11.8.3 PRODUCTS/SERVICES OFFERED 110

11.8.4 KEY DEVELOPMENTS 110

11.8.5 SWOT ANALYSIS 110

11.8.6 KEY STRATEGIES 111

11.9 QIAGEN 112

11.9.1 COMPANY OVERVIEW 112

11.9.2 FINANCIAL OVERVIEW 113

11.9.3 PRODUCTS/SERVICES OFFERED 113

11.9.4 KEY DEVELOPMENTS 114

11.9.5 SWOT ANALYSIS 114

11.9.6 KEY STRATEGIES 114

11.10 SIEMENS AG 115

11.10.1 COMPANY OVERVIEW 115

11.10.2 FINANCIAL OVERVIEW 115

11.10.3 PRODUCTS/SERVICES OFFERED 116

11.10.4 KEY DEVELOPMENTS 116

11.10.5 SWOT ANALYSIS 116

11.10.6 KEY STRATEGIES 117

12 APPENDIX
12.1 REFERENCES 118

12.2 RELATED REPORTS 119